 Shares of Otonomy Inc. plunged 50.1 to pace all premarket decliners, after the biopharmaceutical company said Phase 3 trial of its Ménières disease vertigo treatment failed to meet its primary endpoint. We are disappointed by the top-line results for the primary intent-to-treat population and are undertaking an assessment to understand the difference observed with the per protocol analysis, said Chief Executive David Weber. 